Table 1.
Histologic categorization and clinical details
| Category | Total, % | C3NeF Detected (%) | Low C3 (<0.68 g/L), % | Low C4 (<0.18 g/L), % |
|---|---|---|---|---|
| All participants | 165 (100) | 25 (36.2) | 58 (69.0) | 38 (45.2) |
| IC-PMG | 53 (46.5) | 6 (24.0) | 19 (63.3) | 19 (63.3) |
| C3GN | 39 (34.2) | 8 (33.3) | 19 (67.9) | 8 (28.6) |
| DDD | 22 (19.3) | 10 (58.8) | 16 (84.2) | 9 (47.4) |
| Pediatric onset | 85 (51.5) | 23 (40.4) | 51 (77.2) | 33 (50.0) |
| Immunosuppression | 75 (56.0) | 18 (38.3) | 42 (77.8) | 27 (50.0) |
| ESKD | 42 (25.4) | 5 (41.7) | 6 (42.9) | 1 (7.1) |
| Renal transplant | 30 (18.2) | 4 (57.1) | 4 (44.4) | 0 (0.0) |
| C3NeF detected | 25 (36.2) | — | 23 (92.0) | 11 (44.0) |
Ultrastructural and immunostaining data to allow sub-classification into IC-PMG, C3GN, or DDD were available for 114 participants. Results of clinically accredited C3NeF assays were available for 69 and serum C3 and C4 levels were available for 84 participants, but only a small number of those with ESKD.